Zent R, Yan X, Su Y, Hudson B G, Borza D-B, Moeckel G W, Qi Z, Sado Y, Breyer M D, Voziyan P, Pozzi A
Department of Medicine, Division of Nephrology, Medical Center North, Vanderbilt University, Nashville, Tennessee 37232, USA.
Kidney Int. 2006 Aug;70(3):460-70. doi: 10.1038/sj.ki.5000359. Epub 2006 Jun 14.
Excessive glomerular collagen IV and reactive oxygen species (ROS) production are key factors in the development of diabetic nephropathy. Integrin alpha1beta1, the major collagen IV receptor, dowregulates collagen IV and ROS production, suggesting this integrin might determine the severity of diabetic nephropathy. To test this possibility, wild-type and integrin alpha1-null mice were rendered diabetic with streptozotocin (STZ) (100 mg/kg single intraperitoneal injection), after which glomerular filtration rate (GFR), glomerular collagen deposition, and glomerular basement membrane (GBM) thickening were evaluated. In addition, ROS and collagen IV production by mesangial cells as well as their proliferation was measured in vitro. Diabetic alpha1-null mice developed worse renal disease than diabetic wild-type mice. A significant increase in GFR was evident in the alpha1-null mice at 6 weeks after the STZ injection; it started to decrease by week 24 and reached levels of non-diabetic mice by week 36. In contrast, GFR only increased in wild-type mice at week 12 and its elevation persisted throughout the study. Diabetic mutant mice also showed increased glomerular deposition of collagen IV and GBM thickening compared to diabetic wild-type mice. Primary alpha1-null mesangial cells exposed to high glucose produced more ROS than wild-type cells, which led to decreased proliferation and increased collagen IV synthesis, thus mimicking the in vivo finding. In conclusion, this study suggests that lack of integrin alpha1beta1 exacerbates the glomerular injury in a mouse model of diabetes by modulating GFR, ROS production, cell proliferation, and collagen deposition.
肾小球IV型胶原蛋白过量生成以及活性氧(ROS)产生是糖尿病肾病发展的关键因素。整合素α1β1作为主要的IV型胶原蛋白受体,可下调IV型胶原蛋白和ROS的产生,这表明该整合素可能决定糖尿病肾病的严重程度。为验证这一可能性,将野生型和整合素α1基因敲除小鼠用链脲佐菌素(STZ)(100mg/kg单次腹腔注射)诱导成糖尿病模型,之后评估肾小球滤过率(GFR)、肾小球胶原蛋白沉积以及肾小球基底膜(GBM)增厚情况。此外,还在体外检测了系膜细胞产生的ROS和IV型胶原蛋白以及它们的增殖情况。糖尿病α1基因敲除小鼠比糖尿病野生型小鼠的肾脏疾病更严重。在注射STZ后6周,α1基因敲除小鼠的GFR显著升高;到第24周开始下降,到第36周达到非糖尿病小鼠的水平。相比之下,野生型小鼠仅在第12周时GFR升高,且在整个研究过程中一直保持升高。与糖尿病野生型小鼠相比,糖尿病突变小鼠还表现出IV型胶原蛋白在肾小球的沉积增加以及GBM增厚。暴露于高糖环境的原代α1基因敲除系膜细胞比野生型细胞产生更多的ROS,这导致细胞增殖减少和IV型胶原蛋白合成增加,从而模拟了体内的研究结果。总之,本研究表明,整合素α1β1的缺失通过调节GFR、ROS产生、细胞增殖和胶原蛋白沉积,加剧了糖尿病小鼠模型中的肾小球损伤。